"Daughter" of "Rostecha" - the company "Natsimbio" - may lose the status of the only supplier of blood products, because it did not fulfill its obligations to build a plant in Kirov. In this case, finish it in "Microgen"
The company "Nazimbio", which is part of Rostek, will sell to the Ministry of Health of Russia 31 million doses of flu vaccine for 3.8 billion rubles. The benefits of these vaccines are more than doubtful, but their purchases in Russia grow from year to year.
After leaving the government of the Russian Federation, Igor Shuvalov, a lobbyist for allowing retail chains to sell over-the-counter drugs, his successor Tatyana Golikova withdrew this project from the Cabinet's agenda. That's why the project of Sergei Chemezov and his partner Alexander Vinokurov was torpedoed.
The son-in-law of Foreign Minister Sergey Lavrov, who bought a stake in Magnit from VTB for VTB's money, imposes a grocery network of an unnecessary pharmacy retailer.
The retailer will buy a distributor of SIA Group from its shareholder, Marathon Group, the son-in-law of Russian Foreign Minister Sergey Lavrov. The market reacted to this by the fall of the shares of Magnit.
The son-in-law of Foreign Minister Sergei Lavrov and the raider in combination intend to reshape the pharmacy business in Russia in his favor.
In Moscow, the brothers Magomed and Ziyavudin Magomedov, owners of the Suma Group, were arrested for 2 months on suspicion of organizing a criminal community. Their arrest could hit a relative of Russian Foreign Minister Sergei Lavrov, businessman Alexander Vinokurov, who previously headed Summa for three years.
"Rostegh" and "Marathon" signed an agreement on "Nazimbio".
In Russia, the pharmaceutical market is being monopolized, which will lead to a sharp rise in prices for medicines for the population.
The head of Rostec, Sergey Chemezov, and the son-in-law of Russian Foreign Minister Sergey Lavrov, Alexander Vinokurov, whose villas are located so close to each other, decided to seize the country's pharmaceutical market.
The former president of A1 will get a controlling stake in a major influenza vaccine manufacturer.